NDAORALTABLET
Approved
Jul 1963
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
NEURAMATE (meprobamate) by GenexGen is clinical pharmacology meprobamate is a carbamate derivative which has been shown in animal studies to have effects at multiple sites in the central nervous system including the thalamus and limbic system. Approved for anxiety disorders, for the short-term relief of the symptoms of anxiety, anxiety and 1 more indications. First approved in 1963.
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEURAMATE (meprobamate) is an oral tablet anxiolytic agent approved in 1963 that works as a carbamate derivative affecting multiple CNS sites including the thalamus and limbic system. It is indicated for short-term relief of anxiety disorder symptoms. The drug represents a legacy anxiolytic class now competing against hydroxyzine and benzodiazepines in a crowded market.
LOE Approaching
LOE-stage product with minimal commercial infrastructure; expect right-sizing of brand team and focus on generic transition planning.
Mechanism of Action
CLINICAL PHARMACOLOGY Meprobamate is a carbamate derivative which has been shown in animal studies to have effects at multiple sites in the central nervous system including the thalamus and limbic system.
Worked on NEURAMATE at GenexGen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.